DE69815230D1 - Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten - Google Patents

Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten

Info

Publication number
DE69815230D1
DE69815230D1 DE69815230T DE69815230T DE69815230D1 DE 69815230 D1 DE69815230 D1 DE 69815230D1 DE 69815230 T DE69815230 T DE 69815230T DE 69815230 T DE69815230 T DE 69815230T DE 69815230 D1 DE69815230 D1 DE 69815230D1
Authority
DE
Germany
Prior art keywords
myogenic cells
peptide
behavioral
treatment
pain relief
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815230T
Other languages
English (en)
Other versions
DE69815230T2 (de
Inventor
Peter K Memphis Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAW, PETER K., MEMPHIS, TENN., US
Original Assignee
CELL THERAPY RES FOUNDATION ME
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELL THERAPY RES FOUNDATION ME filed Critical CELL THERAPY RES FOUNDATION ME
Application granted granted Critical
Publication of DE69815230D1 publication Critical patent/DE69815230D1/de
Publication of DE69815230T2 publication Critical patent/DE69815230T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69815230T 1997-08-11 1998-04-07 Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten Expired - Lifetime DE69815230T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5519997P 1997-08-11 1997-08-11
US55199P 1997-08-11

Publications (2)

Publication Number Publication Date
DE69815230D1 true DE69815230D1 (de) 2003-07-10
DE69815230T2 DE69815230T2 (de) 2004-05-06

Family

ID=21996302

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815230T Expired - Lifetime DE69815230T2 (de) 1997-08-11 1998-04-07 Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten

Country Status (7)

Country Link
US (1) US7166279B2 (de)
EP (1) EP0898967B1 (de)
JP (1) JPH11147829A (de)
AT (1) ATE241992T1 (de)
CA (1) CA2225185A1 (de)
DE (1) DE69815230T2 (de)
HK (1) HK1016897A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673604B1 (en) 1999-07-23 2004-01-06 Diacrin, Inc. Muscle cells and their use in cardiac repair
IL154324A0 (en) * 2000-08-08 2003-09-17 Mgvs Ltd Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
CN1612691A (zh) * 2001-11-08 2005-05-04 加利福尼亚大学董事会 纠正心脏传导障碍的方法和组合物
JP4549609B2 (ja) * 2002-04-11 2010-09-22 エスエス製薬株式会社 被覆固形催眠製剤
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
JP2005524496A (ja) * 2002-05-08 2005-08-18 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 非破壊性心伝導ブロック形成用システム及び方法
US6932804B2 (en) * 2003-01-21 2005-08-23 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US7317950B2 (en) * 2002-11-16 2008-01-08 The Regents Of The University Of California Cardiac stimulation system with delivery of conductive agent
CN1972704A (zh) * 2004-04-26 2007-05-30 免疫再生生物科学有限公司 P物质的抗衰老作用
US8889122B2 (en) 2005-05-09 2014-11-18 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20090017080A1 (en) * 2007-03-15 2009-01-15 Paul Robert Tanner Personal care kit having skin care compositions with a readily perceptible difference
WO2008157348A1 (en) * 2007-06-13 2008-12-24 The Procter & Gamble Company Skin treatment device
CN104523365A (zh) * 2008-05-15 2015-04-22 惠氏有限责任公司 提供皮肤益处的方法
US20100224205A1 (en) * 2008-12-09 2010-09-09 Shekhar Mitra Device and methods for modifying keratinous surfaces
JP2012515063A (ja) * 2009-01-16 2012-07-05 ザ プロクター アンド ギャンブル カンパニー 角質表面を改質するための装置及び方法
US20150050300A1 (en) 2013-08-16 2015-02-19 Peter K. Law Disease prevention and alleviation by human myoblast transplantation
CA3024544C (en) 2014-06-13 2020-06-23 The Procter & Gamble Company Apparatus and methods for modifying keratinous surfaces
US20160114349A1 (en) 2014-06-13 2016-04-28 The Procter & Gamble Company Device and methods for depositing materials on hard surfaces
KR101988846B1 (ko) 2014-06-13 2019-06-13 더 프록터 앤드 갬블 캄파니 각질 표면 상의 처리 조성물의 침착을 위한 카트리지
US9924875B2 (en) 2014-06-13 2018-03-27 The Procter & Gamble Company Apparatus and methods for modifying keratinous surfaces
US10518291B2 (en) 2014-06-13 2019-12-31 The Procter & Gamble Company Device and methods for modifying surfaces
US10188192B2 (en) 2014-06-13 2019-01-29 The Procter & Gamble Company Apparatus and methods for modifying keratinous surfaces
WO2015191830A2 (en) 2014-06-13 2015-12-17 The Procter & Gamble Company Treatment compositions, apparatus and methods for modifying keratinous surfaces
US10156036B2 (en) 2014-06-13 2018-12-18 The Procter & Gamble Company Device and methods for applying compositions to fabric surfaces
CA2949129C (en) 2014-06-13 2020-06-30 The Procter & Gamble Company Apparatus and methods for modifying keratinous surfaces
US9949552B2 (en) 2014-07-25 2018-04-24 The Procter & Gamble Company Handheld treatment apparatus for modifying keratinous surfaces
US9955769B2 (en) 2014-07-25 2018-05-01 The Procter & Gamble Company Applicator heads for handheld treatment apparatus for modifying keratinous surfaces
US10314378B2 (en) 2014-07-25 2019-06-11 The Procter & Gamble Company Cartridge assembly for a dispensing device
US10188193B2 (en) 2014-07-25 2019-01-29 The Procter & Gamble Company Applicator heads for handheld treatment apparatus for modifying keratinous surfaces
US11083880B2 (en) 2014-07-25 2021-08-10 The Procter & Gamble Company Angled cartridge assembly for a dispensing device
US9962532B2 (en) 2015-06-11 2018-05-08 The Procter & Gamble Company Cartridges for use in an apparatus for modifying keratinous surfaces
US9949547B2 (en) 2015-06-11 2018-04-24 The Procter & Gamble Company Cartridges for use in an apparatus for modifying keratinous surfaces
WO2016200440A1 (en) 2015-06-11 2016-12-15 The Procter & Gamble Company Device and methods for applying compositions to surfaces
US11116302B2 (en) 2015-06-11 2021-09-14 The Procter & Gamble Company Apparatus and methods for modifying keratinous surfaces
US10391042B2 (en) 2015-12-07 2019-08-27 The Procter & Gamble Company Treatment compositions, apparatus and methods for modifying keratinous surfaces
US9616668B1 (en) 2015-12-07 2017-04-11 The Procter & Gamble Company Servicing cassettes for handheld fluid jet apparatuses for use in modifying surfaces
US10166799B2 (en) 2015-12-07 2019-01-01 The Procter & Gamble Company Service stations for handheld fluid jet apparatuses
US11090238B2 (en) 2017-06-16 2021-08-17 The Procter & Gamble Company Array of cosmetic compositions for camouflaging tonal imperfections
JP6931404B2 (ja) 2017-06-16 2021-09-01 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 可聴フィードバックを有するパーソナルケアデバイス
CA3064495C (en) 2017-06-16 2022-08-30 The Procter & Gamble Company Computer asissted colorimetric make up method for camouflaging skin color deviations
WO2021089162A1 (en) 2019-11-07 2021-05-14 L'oreal Microdermabrasion device for coloring the skin
WO2023102287A1 (en) 2021-12-03 2023-06-08 The Procter & Gamble Company Personal care device with audible feedback

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE77033B1 (en) * 1989-08-16 1997-11-19 Univ Tulane Substance P antagonists
WO1992016547A1 (en) * 1991-03-15 1992-10-01 The Children's Medical Center Corporation Controlling nk-1 receptor-mediated responses and related diagnostics
EP0743820A4 (de) * 1994-12-13 1997-06-11 Peter K Law Myoblast-therapie für säugetierkrankheiten

Also Published As

Publication number Publication date
HK1016897A1 (en) 1999-11-12
US20020044925A1 (en) 2002-04-18
ATE241992T1 (de) 2003-06-15
EP0898967B1 (de) 2003-06-04
CA2225185A1 (en) 1999-02-11
JPH11147829A (ja) 1999-06-02
EP0898967A1 (de) 1999-03-03
DE69815230T2 (de) 2004-05-06
US7166279B2 (en) 2007-01-23

Similar Documents

Publication Publication Date Title
DE69815230D1 (de) Verwendung von transduzierten myogenischen Zellen zur Schmerzhinderung und zur Behandlung der Verhaltungs- und Wahrnehmungsbnormalitäten
Neugebauer et al. Differential sensitization of amygdala neurons to afferent inputs in a model of arthritic pain
Athenstaedt et al. Epidermis of human skin: pyroelectric and piezoelectric sensor layer
Detsch et al. Isoflurane induces dose-dependent changes of thalamic somatosensory information transfer
Bouhassira et al. Heterotopic activation of A delta and C fibres triggers inhibition of trigeminal and spinal convergent neurones in the rat.
DE69324680T2 (de) Elektrische stimulierung zur behandlung von inkontinenz und anderen neuromuskularerkrankungen
DE69841888D1 (de) Gerät zur verabreichung von medikamenten und genen mittels elektroporation
ATE496643T1 (de) Verwendung von antioxidantien zur verhinderung von oxidation und zur reduzierung von wirkstoffzersetzung in wirkstoffhaltigen medizinischen artikeln
DE69604509D1 (de) Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation
ATE420156T1 (de) Methode zur einführung von genetischem material in zellen
ATE298230T1 (de) Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress
Lavrov et al. Integrating multiple sensory systems to modulate neural networks controlling posture
Greenbaum et al. Comparison of iontophoresis of lidocaine with a eutectic mixture of lidocaine and prilocaine (EMLA) for topically administered local anesthesia
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
NZ514091A (en) Vascular adhesion molecules and modulation of their function
NZ515388A (en) Polynucleotides and polypeptides used to stimulate leukocyte growth and to modulate angiogenesis and treat neurological conditions
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
NL8320207A (nl) Werkwijze voor het vervaardigen van aan de huid bevestigbare, in het bijzonder spierkramp stillende preparaten.
DE69614057D1 (de) Selektive Beta3-adrenergische Agonisten
Glass et al. Progressive protrusive tongue exercise does not alter aging effects in retrusive tongue muscles
Iordanishvili Military doctor VV Fialkovsky: life path and contribution to the development of military maxillofacial surgery and dentistry
DE69326188T2 (de) Verwendung von N-Acylderivaten von Aminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von neurogenen endoneuralen Ödemen der peripheren Nerven
Mrig et al. Nail anatomy and physiology
KR20180022601A (ko) 무좀 약물 전달 패치 및 이를 사용하여 약물을 전달하는 방법
Wu et al. Tumor Microenvironment for Melanoma Cells

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LAW, PETER K., MEMPHIS, TENN., US

8364 No opposition during term of opposition
8320 Willingness to grant licences declared (paragraph 23)